Clinical Trial

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 12, 2021 (before its estimated March 2023 completion). Its status may not reflect the trial's current state.
Summary
Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-04-02.
Status change: Not Yet Recruiting → Recruiting 2021-10-11
Trial Details
NCT Number NCT04831437
Lead Sponsor Tehran University of Medical Sciences
Conditions Cervix Uteri Cancer
Enrollment 60 participants
Start Date 2021-04-01
Primary Completion 2023-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2021-10-12